Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of chronic diseases
3.2.1.2 Rising technological advancements in nuclear medicine
3.2.1.3 Rise in healthcare expenditure
3.2.1.4 Favorable government initiatives
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of radiotherapy
3.2.2.2 Short half-life of radiopharmaceuticals
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 Technology landscape
3.6.1 Core technologies
3.6.2 Adjacent technologies
3.7 Future market trends
3.8 Pipeline analysis
3.9 Porter’s analysis
3.10 PESTEL analysis
3.11 Gap analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Diagnostics
5.2.1 Single photon emission computed tomography (SPECT) isotopes
5.2.1.1 TC-99m
5.2.1.2 I-123
5.2.1.3 GA-67
5.2.1.4 TL-201
5.2.1.5 Other SPECT isotopes
5.2.2 Positron emission tomography (PET) isotopes
5.2.2.1 F-18
5.2.2.2 RB-82
5.2.2.3 Other PET isotopes
5.3 Therapeutics
5.3.1 Beta emitters
5.3.1.1 I-131
5.3.1.2 Lu-177
5.3.1.3 Y-90
5.3.1.4 SM-153
5.3.1.5 Re-186
5.3.1.6 Other beta emitters
5.3.2 Brachytherapy isotopes
5.3.2.1 Iridium-192
5.3.2.2 Iodine-125
5.3.2.3 Cesium-131
5.3.2.4 Palladium-103
5.3.2.5 Other brachytherapy isotopes
5.3.3 Alpha emitters
5.3.3.1 RA-223
5.3.3.2 Other alpha emitters
Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Neurology
6.3 Cardiology
6.4 Oncology
6.5 Thyroid
6.6 Pulmonary
6.7 Other applications
Chapter 7 Market Estimates and Forecast, By End Use, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospitals
7.3 Diagnostic centres
7.4 Research institutes
7.5 Other end users
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
1.1.1 Argentina
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
Chapter 9 Company Profiles
9.1 Actinium Pharmaceuticals
9.2 Boston Scientific
9.3 Bracco
9.4 Cardinal Health
9.5 Curium Pharma
9.6 GE Healthcare
9.7 Jubilant Pharma
9.8 Lantheus
9.9 Novartis
9.10 RadioMedix
9.11 RLS Radiopharmacies
9.12 Siemens Healthineers
9.13 Sirtex
9.14 Sun Pharma
9.15 Theragenics
